Sun Pharma share price declined more than 4% on Friday after the drug major reported its Q4 results. Sun Pharma shares fell as much as 4.86% to ₹1,636.30 apiece on the BSE.
Sun Pharmaceutical Industries reported a consolidated net profit of ₹2,154 crore in the fourth quarter of FY25, registering a decline of 19% from ₹2,659 crore in the year ago period.
The company’s revenue from operations in Q4FY25 increased 8% to ₹12,959 crore from ₹11,983 crore, year-on-year (YoY).
Sun Pharmaceutical Industries announced a final dividend of ₹5.50 per equity share. Sun Pharma dividend record date has been fixed as July 7, 2025.
Should you buy Sun Pharma shares after Q4 results?
“We like Sun Pharmaceuticals’ gross margin performance; however, its commercialisation spend is set to increase by $100 million. Delay in Leqselvi launch, potential US policy changes related to brand name drugs and increase in the tax rate are the near-term overhangs on the stock,” Nuvama Institutional Equities said.
The brokerage firm cuts FY26E and FY27E EBITDA margin estimates by 30 bps and 40 bps and forecasts an 8% PAT CAGR over FY25–27E. It retained a ‘Hold’ rating on Sun Pharma shares with an unchanged target price of ₹1,830 apiece.
At 9:25 AM, Sun Pharma share price was trading 3.78% lower at ₹1,655.00 apiece on the BSE.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
